Hollis-Eden Pharmaceuticals Presents Positive Data With APOPTONE(TM) In Preclinical Bone Model Of Late-Stage Prostate Cancer

Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH), the world leader in the development of a new class of small molecule compounds based on endogenous steroid hormones, announced the presentation today of positive data from a preclinical study with APOPTONE? (HE3235), its lead investigational drug candidate for cancer.

More: continued here

Filed under: Prostate on April 17th, 2008